In this episode, I’ll discuss an article about IV push piperacillin-tazobactam.
Safety and tolerability of i.v. push piperacillin/tazobactam within an emergency department
Lead author: William Blake Hays
Published in American Journal of Health-System Pharmacy May 2020
Piperacillin/tazobactam is typically administered via IV piggyback over 30 minutes or more increasingly common via extended infusion over 4 hours.
In order to meet first dose antibiotic timeliness goals, many practitioners prefer IV push antibiotics. However, data for IV push administration of piperacillin/tazobactam is lacking and there is concern that the high osmolality of the reconstituted solution could cause IV push-related side effects. The authors of this study sought to retrospectively assess the safety and tolerability of piperacillin/tazobactam administered peripherally by IVP.
The study was designed as a single-center retrospective chart review of patients who received administration of a single dose of IVP piperacillin/tazobactam through a peripheral line in an emergency department.
Over 1800 patients who received 1 dose of IVP piperacillin/tazobactam were identified and 300 of these patients were randomly selected for assessment of safety and tolerability. All but one patient tolerated IVP piperacillin/tazobactam for a tolerability rate of 99.7%. The one patient with a side effect had an allergic reaction which included itching and hives. There were no infusion-related reactions including phlebitis or IV site reactions that were documented.
The authors concluded:
IVP administration of piperacillin/tazobactam through a peripheral site is safe and tolerable for adult patients.
Although ongoing administration of piperacillin/tazobactam is likely best done as an extended infusion to provide adequate time above MIC, IV push administration of the first dose could allow for a more timely administration and in circumstances with limited IV access and the need for additional antibiotics such as vancomycin could allow for a faster time to completion of administration of broad-spectrum antibiotics.
While the benefits of this strategy have not been demonstrated, it is apparent that safety in terms of adverse effects from the IV push route appears to be a non-issue. What remains unclear is, if the first dose of piperacillin/tazobactam was given IV push and subsequent doses are given IV over 4 hours every 8 hours, when is the ideal timing of the 2nd dose? Likely waiting 8 hours to start the 2nd dose is too long.
If your institution adopts this practice consider coming to a consensus of when to schedule the 2nd dose to avoid an unnecessarily long period where the antibiotic concentration is below the MIC.
To access my free download area with 20 different resources to help you in your practice, go to pharmacyjoe.com/free.
If you like this post, check out my book – A Pharmacist’s Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies.
Leave a Reply